Univariate and multivariate analysis of prognostic factors in 75 transformed MF patients presenting with only skin lesions
| Characteristic . | No. . | Median survival, mo . | DSS, % . | Univariate analysis DSS . | Multivariate analysis DSS . | OS, % . | Univariate analysis OS . | Multivariate analysis OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Sex | .390 | .962 | ||||||||||||||
| Male | 51 | 27 (1-235) | 73 | 46 | 46 | 1 | 60 | 36 | 22 | 1 | ||||||
| Female | 24 | 22.5 (2-160) | 60 | 39 | 39 | 1.4 (0.7-2.7) | 56 | 37 | 37 | 1 (0.6-1.9) | ||||||
| Age | .515 | .084 | .012 | |||||||||||||
| < 60 y | 19 | 45 (4-164) | 48 | 48 | 48 | 1 | 42 | 42 | 42 | 1 | 1 | |||||
| ≥ 60 y | 56 | 21 (1-235) | 65 | 42 | 42 | 1.3 (0.6-2.8) | 53 | 32 | 20 | 1.9 (0.9-3.7) | 2.8 (1.8-6.1) | |||||
| Time interval between MF and LCT | .050 | .830 | .180 | .537 | ||||||||||||
| ≤ 24 mo | 48 | 31 (2-164) | 80 | 51 | 51 | 1 | 1 | 67 | 49 | 21 | 1 | 1 | ||||
| > 24 mo | 27 | 20 (1-235) | 51 | 31 | 31 | 2.0 (1.0-3.8) | 1.1 (0.5-2.4) | 45 | 27 | 22 | 1.5 (0.8-2.6) | 1.2 (0.6-2.5) | ||||
| Clinical stage at LCT | .205 | .220 | .207 | .127 | ||||||||||||
| IB | 10 | 48 (11-160) | 77 | 64 | 64 | 1 | 1 | 77 | 64 | 38 | 1 | 1 | ||||
| IIB | 65 | 25 (1-235) | 68 | 40 | 40 | 2.2 (0.7-7.0) | 2.2 (0.6-6.4) | 57 | 32 | 25 | 1.8 (0.7-4.6) | 2.1 (0.8-5.6) | ||||
| CD30 expression | .008 | .006 | .026 | .027 | ||||||||||||
| Positive | 36 | 38 (1-160) | 90 | 57 | 57 | 1 | 1 | 76 | 50 | 33 | 1 | 1 | ||||
| Negative | 39 | 21 (2-235) | 54 | 33 | 33 | 2.6 (1.3-5.6) | 3.2 (1.4-7.1) | 45 | 24 | 21 | 1.9 (1.0-3.5) | 2.1 (1.1-3.9) | ||||
| Folliculotropic MF | .014 | < .001 | .178 | .001 | ||||||||||||
| Absent | 53 | 27 (1-235) | 73 | 55 | 55 | 1 | 1 | 60 | 43 | 29 | 1 | 1 | ||||
| Present | 22 | 23.5 (2-134) | 61 | 22 | 22 | 2.3 (1.2-4.6) | 4.0 (1.9-8.2) | 58 | 21 | 21 | 1.5 (0.8-2.8) | 3.4 (1.7-7.0) | ||||
| % large cells in infiltrate | .784 | .789 | ||||||||||||||
| < 25 (nodules) | 7 | 26 (11-44) | 100 | 1 | 80 | 1 | ||||||||||
| 25-75 | 32 | 27 (2-235) | 71 | 49 | 49 | 0.67 (0.2-2.1) | 60 | 41 | 29 | 0.74 (0.3-2.0) | ||||||
| > 75 | 36 | 24.5 (1-164) | 62 | 46 | 46 | 0.75 (0.2-2.2) | 55 | 38 | 28 | 0.71 (0.3-1.9) | ||||||
| Extent of skin tumors | .024 | .024 | .009 | .002 | ||||||||||||
| Solitary | 19 | 30 (5-164) | 87 | 69 | 69 | 1 | 1 | 78 | 62 | 62 | 1 | 1 | ||||
| Localized | 22 | 29 (1-235) | 84 | 49 | 49 | 1.6 (0.5-5.0) | 1.2 (0.4-4.0) | 69 | 35 | 35 | 1.7 (0.7-4.4) | 0.9 (0.3-2.6) | ||||
| Generalized | 34 | 20.5 (2-100) | 52 | 30 | 3.4 (1.3-9.5) | 3.4 (1.2-9.7) | 44 | 25 | 3.4 (1.5-7.8) | 3.3 (1.3-8.0) | ||||||
| Characteristic . | No. . | Median survival, mo . | DSS, % . | Univariate analysis DSS . | Multivariate analysis DSS . | OS, % . | Univariate analysis OS . | Multivariate analysis OS . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | 2 y . | 5 y . | 10 y . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Sex | .390 | .962 | ||||||||||||||
| Male | 51 | 27 (1-235) | 73 | 46 | 46 | 1 | 60 | 36 | 22 | 1 | ||||||
| Female | 24 | 22.5 (2-160) | 60 | 39 | 39 | 1.4 (0.7-2.7) | 56 | 37 | 37 | 1 (0.6-1.9) | ||||||
| Age | .515 | .084 | .012 | |||||||||||||
| < 60 y | 19 | 45 (4-164) | 48 | 48 | 48 | 1 | 42 | 42 | 42 | 1 | 1 | |||||
| ≥ 60 y | 56 | 21 (1-235) | 65 | 42 | 42 | 1.3 (0.6-2.8) | 53 | 32 | 20 | 1.9 (0.9-3.7) | 2.8 (1.8-6.1) | |||||
| Time interval between MF and LCT | .050 | .830 | .180 | .537 | ||||||||||||
| ≤ 24 mo | 48 | 31 (2-164) | 80 | 51 | 51 | 1 | 1 | 67 | 49 | 21 | 1 | 1 | ||||
| > 24 mo | 27 | 20 (1-235) | 51 | 31 | 31 | 2.0 (1.0-3.8) | 1.1 (0.5-2.4) | 45 | 27 | 22 | 1.5 (0.8-2.6) | 1.2 (0.6-2.5) | ||||
| Clinical stage at LCT | .205 | .220 | .207 | .127 | ||||||||||||
| IB | 10 | 48 (11-160) | 77 | 64 | 64 | 1 | 1 | 77 | 64 | 38 | 1 | 1 | ||||
| IIB | 65 | 25 (1-235) | 68 | 40 | 40 | 2.2 (0.7-7.0) | 2.2 (0.6-6.4) | 57 | 32 | 25 | 1.8 (0.7-4.6) | 2.1 (0.8-5.6) | ||||
| CD30 expression | .008 | .006 | .026 | .027 | ||||||||||||
| Positive | 36 | 38 (1-160) | 90 | 57 | 57 | 1 | 1 | 76 | 50 | 33 | 1 | 1 | ||||
| Negative | 39 | 21 (2-235) | 54 | 33 | 33 | 2.6 (1.3-5.6) | 3.2 (1.4-7.1) | 45 | 24 | 21 | 1.9 (1.0-3.5) | 2.1 (1.1-3.9) | ||||
| Folliculotropic MF | .014 | < .001 | .178 | .001 | ||||||||||||
| Absent | 53 | 27 (1-235) | 73 | 55 | 55 | 1 | 1 | 60 | 43 | 29 | 1 | 1 | ||||
| Present | 22 | 23.5 (2-134) | 61 | 22 | 22 | 2.3 (1.2-4.6) | 4.0 (1.9-8.2) | 58 | 21 | 21 | 1.5 (0.8-2.8) | 3.4 (1.7-7.0) | ||||
| % large cells in infiltrate | .784 | .789 | ||||||||||||||
| < 25 (nodules) | 7 | 26 (11-44) | 100 | 1 | 80 | 1 | ||||||||||
| 25-75 | 32 | 27 (2-235) | 71 | 49 | 49 | 0.67 (0.2-2.1) | 60 | 41 | 29 | 0.74 (0.3-2.0) | ||||||
| > 75 | 36 | 24.5 (1-164) | 62 | 46 | 46 | 0.75 (0.2-2.2) | 55 | 38 | 28 | 0.71 (0.3-1.9) | ||||||
| Extent of skin tumors | .024 | .024 | .009 | .002 | ||||||||||||
| Solitary | 19 | 30 (5-164) | 87 | 69 | 69 | 1 | 1 | 78 | 62 | 62 | 1 | 1 | ||||
| Localized | 22 | 29 (1-235) | 84 | 49 | 49 | 1.6 (0.5-5.0) | 1.2 (0.4-4.0) | 69 | 35 | 35 | 1.7 (0.7-4.4) | 0.9 (0.3-2.6) | ||||
| Generalized | 34 | 20.5 (2-100) | 52 | 30 | 3.4 (1.3-9.5) | 3.4 (1.2-9.7) | 44 | 25 | 3.4 (1.5-7.8) | 3.3 (1.3-8.0) | ||||||
MF indicates mycosis fungoides; LCT, large-cell transformation; DSS, disease specific survival; OS, overall survival; and HR, Hazard ratio